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Background: Increasing numbers of HIV-infected patients in sub-Saharan Africa are exposed to antiretroviral
therapy (ART), but there are few data on lipid changes on first-line ART, and even fewer on second-line.
Methods: DART was a randomized trial comparing monitoring strategies in Ugandan/Zimbabwean adults initiating
first-line ART and switching to second-line at clinical/immunological failure. We evaluated fasting lipid profiles at
second-line initiation and ≥48 weeks subsequently in stored samples from Zimbabwean patients switching before
18 September 2006.
Results: Of 91 patients switched to second-line ART, 65(73%) had fasting samples at switch and ≥48 weeks, 14(15%)
died or were lost <48 weeks, 10(11%) interrupted ART for >14 days and 2(2%) had no samples available. 56/65(86%)
received ZDV/d4T + 3TC + TDF first-line, 6(9%) ZDV/d4T + 3TC + NVP and 3(5%) ZDV + 3TC with TDF and NVP.
Initial second-line regimens were LPV/r + NNRTI in 27(41%), LPV/r + NNRTI + ddI in 33(50%) and LPV/r + TDF + ddI/
3TC/ZDV in 6(9%). At second-line initiation median (IQR) TC, LDL-C, HDL-C and TG (mmol/L) were 3.3(2.8-4.0),
1.7(1.3-2.2), 0.7(0.6-0.9) and 1.1(0.8-1.9) respectively. Levels were significantly increased 48 weeks later, by
mean (SE) +2.0(0.1), +1.1(0.1), +0.5(0.05) and +0.4(0.2) respectively (p < 0.001; TG p = 0.01). 3% at switch vs 25%
48 weeks later had TC >5.2 mmol/L; 3% vs 25% LDL-C >3.4 mmol/L and 91% vs 41% HDL-C <1.1 mmol/L (p < 0.001).
Similar proportions had TG >1.8 mmol/L (0 vs 3%) and TC/HDL-C ≥5 (40% vs 33%) (p > 0.15).
Conclusion: Modest lipid elevations were observed in African patients on predominantly LPV/r + NNRTI-based
second-line regimens. Routine lipid monitoring during second-line ART regimens may not be warranted in this
setting but individual cardiovascular risk assessment should guide practice.
Keywords: Antiretroviral therapy, Lipid profile changes, Protease inhibitors, Non-nucleoside reverse transcriptase
inhibitors, African settingIntroduction
HIV infection in sub-Saharan Africa and in particular in
Central and Southern Africa continues to exact a heavy
burden [1]. The past decade has seen a rapid expansion
of antiretroviral therapy (ART) rollout particularly in
sub-Saharan Africa [1]. This has resulted in a reduction* Correspondence: zargomo@gmail.com; jhakim@mweb.co.zw
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of life [1].
With an estimated 9.7 million people in lower and
middle income countries on ART by the end of 2012 the
adverse consequences of treatment are likely to become
increasingly significant. Increasing use of ART has been
accompanied by the emergence of a range of complica-
tions associated with treatment among which short and
long-term cardiovascular complications have been ob-
served [2]. Many of these have been poorly documented
in the sub-Saharan African setting.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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which has an impact on the risk of cardiovascular dis-
ease [3-8]. The severity of hyperlipidaemia appears to be
associated with the type of ART regimen in use. Many
ART regimens result in changes in lipid levels, although
protease inhibitor based (PI) regimens have been ob-
served to influence lipid changes to a greater degree
than other ART regimens [7,9,10].
There is a paucity of literature documenting lipid
changes in HIV infection and during ART in sub-
Saharan Africa. A few reports have, however, began to
explore lipid and body-shape changes during ART ex-
posure in this setting [11-15]. These reports predomin-
antly focus on first-line ART regimens including in
children. Whilst <3% of those on ART are currently re-
ceiving second-line, given the substantial numbers cur-
rently on first-line, this will increase significantly over
the next decade. There is thus an urgent need for more
studies that assess lipid changes during the use of vari-
ous combinations of antiretroviral drugs in Sub-Saharan
African patients taking second-line regimens.
This study aimed to conduct preliminary investigations
within the DART Trial (Development of Antiretroviral
Therapy in Africa) [16], a randomised trial of routine
versus clinically driven laboratory monitoring of anti-
retroviral therapy in adults with HIV infection in Africa.
3,316 ART-naive adults with CD4 < 200 cells/mm3 from
Uganda and Zimbabwe initiated first-line ART with
Combivir (co-formulated zidovudine + lamuvudine) plus
tenofovir (n = 2469), abacavir (n = 300) or nevirapine
(n = 547). WHO ART guidelines [17] defined failure
triggered criteria to trigger switch to second-line ART
(new/recurrent WHO 4 events in all; CD4 < 100 cells/mm3
in the 50% randomised to routine laboratory (including
CD4) monitoring). In this sub-study we assayed lipids
in fasting samples from Zimbabwean participants at
switch to second-line ART and ≥48 weeks later. The
objective was to determine the magnitude and determi-
nants of lipid changes in patients switched to second-




This is an observational prospective sub-study on partic-
ipants who switched to lopinavir/ritonavir (LPV/r)-
containing second-line ART at clinical failure (WHO
4 event) in those randomised to clinically driven monitor-
ing only (CDM); or at clinical or immunological failure
(CD4 < 100 cells/mm3) in those randomised to laboratory
and clinical monitoring (LCM) in the DART trial. Most
participants were on LPV/r with a non-nucleoside reverse
transcriptase inhibitor (NNRTI) with or without an add-
itional nucleoside reverse transcriptase inhibitor (NRTI)following triple NRTI first-line regimens. Zimbabwean pa-
tients were included in the sub-study if they switched
to second-line ART before 18 September 2006, allowing
48 weeks follow-up through September 2007, did not
interrupt LPV/r-containing ART for >14 days during the
first 48 weeks on second-line, and had fasting samples
available at switch to second-line and 48 weeks later.
Demographic and baseline variables were obtained from
the main DART database.
Determination of lipid profiles
Fasting blood samples were collected into 10 ml EDTA
tubes after a 10 hour fast (no intake except for water).
Plasma was separated at 3000 g for 10 minutes within
an hour of collection. The plasma aliquots were stored
at -80°C until analysis was performed. Total choles-
terol (TC), low density lipoprotein–cholesterol (LDL-C),
high density lipoprotein–cholesterol (HDL-C) and tri-
glycerides (TG) were determined on a Beckman Coulter
Synchron CX5 analyzer using appropriate Beckman
Coulter reagents (Beckman Coulter, Johannesburg, South
Africa).[Synchrone CX].
Definitions
Body mass index (BMI) was defined by the formula (body
weight in Kg)/(height in m)2 and categorized as <18.5-
underweight, 18.5-24.9-normal, 25.0-29.9-overweight, ≥30.0-
obese. To enable comparison with the published litera-
ture, criteria from the Third Report of the US National
Cholesterol Education Program [18] were used to de-
fine abnormal lipid levels as follows: TC ≥5.2 mmol/L,
LDL-C ≥3.4 mmol/L, HDL-C ≤1.1, TG ≥1.8 and TC/
HDL-C ratio of ≥5 [18]. The Division of AIDS toxicity
tables were used to grade lipid toxicity levels [19]. The
following abbreviations were used for antiretroviral
classes and drugs: nucleoside reverse transcriptase in-
hibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs), Protease Inhibitors (PIs), zidovu-
dine (ZDV), lamivudine (3TC), tenofovir (TDF), stavudine
(d4T), didanosine (ddI), nevirapine (NVP), efavirenz (EFV),
lopinavir/ritonavir (LVP/r).
Statistical analysis
Plasma lipid levels at switch to second-line ART and
48 weeks subsequently were summarised using medians
and interquartile ranges, and compared across groups de-
fined by demographic and other characteristics using the
Kruskal-Wallis test. Changes in lipid levels between switch
to second-line and 48 weeks were compared using paired
t-tests. Multivariable linear regression models were used to
identify factors independently associated with changes in
lipid levels from switch to ≥48 weeks. All models were ad-
justed for baseline lipid levels. Analyses were performed
using STATA 10 (StataCorp, College Station, TX).
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Results
Ninety-one DART participants at the Zimbabwe site
were switched to second-line ART before 18 September
2006, of whom 65 (71%) had fasting samples at switch
and ≥48 weeks later and were included in this sub-study.
26 participants were excluded for the following reasons;
14 (15%) died (no cardiovascular related deaths) or
were lost to follow up <48 weeks after switch; 10 (11%)
interrupted ART for >14 days; 2 (2%) did not have sam-
ples available at both time points. Of the 65 partici-
pants included, 34 (52%) were males and 31 (48%)
females. The median (IQR) age at switch was 39 (35-
44) years, and participants had been on first-line ART
for a median (range) 2.2 years (0.9-3.1 years). Charac-
teristics at switch to second-line ART are shown in
Table 1. At switch, 16% of participants were under-
weight according to BMI and an equal proportion, 16%,
were overweight or obese. 88% of participants had CD4
counts <100 cells/mm3.
First-line and second-line ART
56 (86%) of the 65 included participants received ZDV/
d4T + 3TC + TDF during first-line ART, 6 (9%) ZDV/
d4T + 3TC +NVP, and 3(5%) ZDV + 3TC with TDF and
NVP at different stages, mostly due to development of
TB or NVP-associated rash. Initial second-line regimens
were LPV/r + NNRTI in 27(41%), LPV/r + NNRTI + ddI
in 33(50%) and LPV/r + TDF + ddI/3TC/ZDV in 6(9%)
participants, reflecting the fact that most patients had
received 3NRTI first-line. Of the patients on second-line
regimens which included an NNRTI, 9/60 (15%) were
on EFV and 51/60 (85%) on NVP. During second-line
ART, 5 (8%) patients substituted from NVP to EFV; 1
from ddI to d4T, and 1 from EFV to d4T and back to
d4T during the course of pregnancy. Only 4 participants
had any time off ART during second-line (2 were for
4 days, 1 for 9 days and 1 for 14 days).
Lipids at switch to second-line ART
At switch to second-line, median (IQR) (mmol/L)
plasma fasting lipid concentrations were: TC 3.3 (2.8-
4.0), LDL-C 1.7 (1.3-2.2), HDL-C 0.7 (0.6-0.9), TG 1.1
(0.8-1.9), TC/HDL-C ratio 4.6 (4.0-5.6) (Table 1). Using
NECP [18] criteria TC was >5.2 mmol/L in 2/65 (3%)
participants, LDL-C was >3.4 mmol/L in 2/65 (3%) partici-
pants, HDL-C was <1.1 mmol/L in 94% of participants;TC/HDL-C ratio was <5 in 30/65 (60%) participants; and
no participant had abnormally raised TG levels.
In the univariate analyses at switch to second-line
ART regimens, women had significantly higher TC
(+0.8 mmol/L, p = 0.004), LDL-C (+0.6 mmol/L, p = 0.006)
and HDL-C (+0.1 mmol/L, p = 0.05). TG levels were not
significantly higher (+0.5) mmol/L, p = 0.80 in men at
switch to second-line ART regimens. There were no statis-
tically significant differences in lipid levels according to age
or CD4 count at switch to second-line ART regimens
(Table 1); but LDL-C was higher in those with higher BMI
at switch (p = 0.04), with similar non-significant trends for
TC and TG.
Patients who had received ART combinations contain-
ing NVP in first-line had higher HDL-C (+0.2 mmol/L,
p = 0.02) at switch than those who had received ART
combinations containing TDF and other NRTIs only
(Table 1). Of note there was a statistically significantly
higher TC (p = 0.04) in patients who had received ZDV/
d4T + 3TC + TDF first-line.
Anthropometric, immunologic and lipid profile changes
from switch to ≥48 weeks of second-line ART
Fasting lipid profiles (TC, LDL-C, HDL-C, TC/HDL-C
ratio and TG) after ≥48 weeks of second-line ART are
shown in Table 2; TC, LDL-C and HDL-C remained higher
in women persisted, and associations between higher TC,
LDL-C and TG and higher BMI strengthened. Lipid levels
were significantly increased after ≥48 weeks of second-
line ART, by (mean mmol/L) TC +2.0, LDL-C +1.1,
HDL-C +0.5 (all p < 0.001) and TG +0.40 (p = 0.01)
(Table 3, Figure 1). The percentage increase in lipid
levels after ≥48 weeks of second-line ART was TC 59%,
LDL-C 61%, HDL-C 71% and TG 29% (Table 3). There
was no significant change in TC/HDL-C ratio, p = 0.94
(Table 3).
Comparing switch vs ≥48 weeks of second-line ART,
the proportion of participants with TC >5.2 mmol/L was
3% vs 60% respectively, and 3% vs 25% respectively
had LDL-C >3.4 mmol/L (both p < 0.001). However, as
HDL-C also increased, the proportion of participants
with HDL-C <1.1 mmol/L decreased after ≥48 weeks
of second-line ART from 94% vs 41% (p < 0.001).
There were no significant changes in the proportion
with TG >1.8 mmol/L (0 vs 3% respectively, p = 0.16) or
TC/HDL-C ratio ≥5 (40% vs 33% respectively, p = 0.17).
DAIDS toxicity criteria showed a corresponding but small
shift to higher grades 3 and 4.
Factors associated with changes in lipid profiles on
second-line
We performed multivariable regression analyses includ-
ing all demographic and clinical factors weakly (p < 0.20)
associated with a change in at least one lipid variable
Table 1 Demographic data, BMI, CD4 count and plasma lipid levels at initiation of second-line ART
(switch from first-line ART)








†P TC/HDL-C ratio mean
(se)
†P
All 65 3.4 (0.1) 1.8 (0.1) 0.7 (0.03) 1.4 (0.1) 4.9 (0.2)
Sex
Females 31 (48%) 3.8 (0.2) 0.004 2.1 (0.2) 0.006 0.8 (0.04) 0.05 1.3 (0.1) 0.80 4.9 (0.2) 0.66
Males 34 (52%) 3.0 (0.1) 1.5 (0.1) 0.7 (0.04) 1.8 (0.2) 4.8 (0.3)
Age (years)
<35 17 (26%) 3.4 (0.2) 0.61 1.7 (0.2) 0.7 0.8 (0.1) 0.78 1.3 (0.3) 0.10 4.8 (0.4) 0.46
35-44 33 (51%) 3.4 (0.2) 1.9 (0.1) 0.7 (0.1) 1.5 (0.1) 4.9 (0.2)
≥45 15 (23%) 3.2 (0.4) 1.7 (0.2) 0.7 (0.1) 1.5 (0.3) 4.8 (0.3)
¥BMI (kg/m2)
<18.5 10 (16%) 3.0 (0.3) 0.11 1.6 (0.2) 0.04 0.8 (0.1) 0.33 1.0 (0.3) 0.46 4.2 (0.4) 0.45
18.5-24.9 41 (67%) 3.4 (0.1) 1.8 (0.1) 0.7 (0.1) 1.6 (0.2) 4.9 (0.2)
25-29.9 8 (13%) 3.4 (0.3) 1.8 (0.2) 0.7 (0.1) 1.4 (0.2) 4.8 (0.2)
30-39.9 2 (3%) 4.0 (0.1) 2.4 (0.1) 0.7 (0.1) 1.7 (0.9) 5.5 (0.5)
CD4 cell/mm3
<100 57 (88%) 3.3 (0.1) 0.95 1.7 (0.1) 0.47 0.7 (0.02) 0.64 1.5 (0.1) 0.85 4.8 (0.2) 0.73
100-199 6 (9%) 3.9 (0.9) 2.1 (0.6) 0.7 (0.1) 1.4 (0.2) 6.0 (1.0)
≥200 2 (3%) 4.0 (0.6) 2.2 (0.7) 1.2 (0.1) 0.6 (0.2) 3.5 (0.8)
ART-during first-line
ZDV/d4T + 3TC + TDF 56 (86%) 3.4 (0.1) 0.59 1.8 (0.1) 0.30 0.7 (0.03) 0.02 1.5 (0.1) 0.04 5.0 (0.2) 0.09
±ZDV/d4T++NVP 9 (14%) 3.4 (0.2) 1.9 (0.2) 0.9 (0.10) 0.9 (0.1) 4.0 (0.4)
†P-values for continuous BMI, Age and CD4 vs lipids calculated using Spearman correlation.
¥4 participants with missing weight at initiation of second –line ART.
±Including 3 patients who had substituted NVP- > TDF for hepatotoxicity (2) or anti-TB therapy (1) during first-line.
TC: total cholesterol, LDL-C: low density lipoprotein–cholesterol, HDL-C: high density lipoprotein–cholesterol, TG: triglyceride, BMI: Body mass index. All lipid levels
are expressed in mmol/L.
Table 2 BMI, CD4 Count and lipid levels at ≥48 weeks on second-line ART
48 weeks after switch
to second-line








†P TC/HDL-C ratio mean
(se)
†P
All 65 5.4 (0.2) 2.9 (0.1) 1.2 (0.05) 1.9(0.2) 4.9 (0.3)
Sex
Females 31 (48%) 5.8 (0.2) 0.03 3.2 (0.2) 0.003 1.3 (0.07) 0.03 1.8 (0.2) 0.71 4.6 (0.2) 0.69
Males 34 (52%) 5.1 (0.2) 2.5 (0.1) 1.1 (0.06) 2.0 (0.2) 5.1 (0.4)
BMI (kg/m2)
<18.5 4 (6%) 4.8 (0.4) 0.04 2.6 (0.5) 0.05 1.2 (0.3) 0.57 1.0 (0.2) 0.003 4.6 (0.9) 0.55
18.5-24.9 36 (56%) 5.2 (0.2) 2.7 (0.2) 1.2 (0.1) 1.5 (0.1) 5.0 (0.4)
25-29.9 21 (32%) 5.8 (0.3) 3.1 (0.2) 1.2 (0.1) 2.4 (0.3) 4.8 (0.4)
30-39.9 4 (6%) 5.9 (0.3) 3.1 (0.4) 1.2 (0.4) 2.8 (1.1) 5.0 (1.0)
CD4 cell/mm3
<100 2 (3%) 4.6 (0.9) 0.93 2.6 (0.6) 0.28 1.1 (0.1) 0.10 0.8 (0.02) 0.24 4.2 (1.1) 0.31
100-199 10 (15%) 5.7 (0.2) 3.0 (0.2) 1.4 (0.1) 1.8 (0.5) 4.1 (0.4)
≥200 53 (82%) 5.4 (0.2) 2.8 (0.1) 1.2 (0.1) 1.9 (0.2) 5.1 (0.3)
TC: total cholesterol, LDL-C: low density lipoprotein–cholesterol, HDL-C: high density lipoprotein–cholesterol, TG: triglyceride, BMI: Body mass index. All lipid levels
are expressed in mmol/L.
†P-values for continuous BMI and CD4 vs. lipids calculated using Spearman correlation.
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Table 3 Plasma Lipid levels changes from switch









n = 65 n = 65 n = 65
TC 3.4 (1.0) 5.4 (1.2) +2.0 (0.1) 59% <0.001
LDL-C 1.8 (0.7) 2.8 (0.9) +1.1 (0.1) 61% <0.001
HDL-C 0.7 (0.2) 1.2 (0.4) +0.5 (0.05) 71% <0.001
TG 1.4 (1.0) 1.9 (1.3) +0.4 (0.2) 29% 0.01
TC/HDLC-C 4.9 (1.4) 4.9 (2.1) +0.0 (0.3) 0% 0.94
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analysis, and adjusting for baseline (switch) values
(Table 4). All models thus included sex, age, lipid levels
at switch to second-line ART, BMI at ≥48 weeks, and
type of second-line regimen (EFV vs NVP vs no NNRTI;
ddI vs no ddI). Controlling for baseline lipid levels and
other factors, in comparison to men, women had sig-
nificantly greater increases in LDL-C (+0.5, p = 0.04)
after ≥48 weeks on second-line ART. Older patients
had significantly greater increases in TC (+0.4, p = 0.02),
LDL-C (+0.3, p = 0.06) and HDL-C (+0.1, p = 0.02)
after ≥48 weeks on second-line ART. There was a trend
towards greater TG increases (+0.08 mmol/L, p = 0.07)
and smaller HDL-C increases (-0.02 mmol/L, p = 0.08)
in those with higher BMI.
Patients taking LPV/r with NNRTIs appeared to
have greater increases in TC, LDL-C and HDL-C than
those taking LPV/r with NRTIs (numbers were howeverFigure 1 Fasting plasma lipids at switch to second-line and 48 weeks lat
(LDL-C), High-density lipoprotein-cholesterol (HDL-C) and triglycerides (TG) leve
second-line ART regimens (p < 0.001).small). Those taking EFV appeared to have larger increases
in LDL-C (+0.9 mmol/L, p = 0.03) than HDL-C (+0.4,
p = 0.02).
Discussion
This study reports our observations of lipid changes fol-
lowing switch from first-line ART to second-line regi-
mens containing new classes of antiretroviral drugs with
a view to making recommendations on lipid level meas-
urement during second-line ART in an African setting.
It should be noted that the DART study (DART) was
conducted at a time when triple- nucleoside regimens
were in vogue and hence second-line regimens con-
tained a combination of boosted-PIs and NNRTI with or
without the addition of NRTIs.
It is well established that increased TC, LDL-C, TC/
HDL-C ratio and TG are associated with an increased
risk of cardiovascular events, while raised HDL-C re-
duces this risk [18]. These observations have been made
in large studies that indicate these associations to hold
across all ethnicities [20]. Observations in resource-rich
countries show that HIV infection is associated with low
serum lipid levels depending on degree of immunosup-
pression and viraemia [6,7]. Several studies in African
settings have made similar observations on patients be-
fore ART initiation [21-24]. ART has transformed the
lives of HIV infected patients but changes in lipid levels
are a recognised complication of ART [6,9,25]. Al-
though the belief is that Africans in sub-Saharan Africa
generally have low lipid levels, there is evidence that
this is changing in response to many factors includinger. Footnote 1: Total Cholesterol (TC), Low-density lipoprotein-cholesterol
ls were statistically significantly increased ≥48 weeks on switching to
Table 4 Multivariable linear regression analyses for factors associated with changes in lipid levels from switch
to ≥48 weeks on second-line ART
At switch to second- line* n (%) or median (IQR) TC effect (se) P LDL-C effect (se) P HDL-Ceffect (se) P TG effect (se) P
Gender
Females 32 (48%) +04 (0.3) 0.14 +0.5 (0.2) 0.04 +0.1 (0.08) 0.26 −0.07 (0.3) 0.81
Age (per 10 year increase) 38 (34-43) +0.4 (0.2) 0.02 +0.3 (0.1) 0.06 +0.1 (0.06) 0.02 −0.04 (0.2) 0.87
BMI (kg/m2) per 2 units 21 (17-26) +0.02 (0.03) 0.47 +0.02 (0.03) 0.41 −0.02 (0.01) 0.08 +0.08 (0.04)§ 0.07
NVP 50 (77%) +1.3 (0.4) 0.004 +0.6 (0.3) 0.10 +0.6 (0.2) <0.001 +0.4 (0.6) 0.43
EFV 9 (14%) +1.6 (0.5) 0.003 +0.9 (0.4) 0.03 +0.4 (0.2) 0.02 +0.4 (0.6) 0.57
ddI 34 (52%) −0.04 (0.3) 0.88 −0.1 (02) 0.54 −0.1 (0.1) 0.21 +0.2 (0.3) 0.54
Al l models are adjusted for baseline lipid level.
§BMI at week 48 (rather than at switch to second-line) as this was a better predictor.
*Reference category: man aged 40 years with BMI 25 at switch, receiving LPV/r plus NRTIs (no NNRTI) without ddI as their second-line regimen.
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increasing prevalence of hypertension, diabetes and
smoking [26].
At baseline (switch to second-line ART after a median
of 2.2 years of first-line ART) the TC, LDL-C and TG
levels in our study participants were low which is con-
sistent with a low atherogenic risk [18]. The HDL-C
levels were however low reflecting a high atherogenic
risk. The combination of low TC and low HDL-C re-
sulted in a TC/HDL-C ratio of 4.9 which is reflective of
a borderline [18], but relatively high atherogenic risk if
one considers the generally low TC and LDL-C levels.
After ≥48 weeks of second-line ART predominantly con-
sisting of a combination of PI/r and NNRTI with or
without NRTIs there was a marked increase in lipid
levels; relative increases of TC 59%, LDL-C 61%, HDL-C
71% and TG 29%. The TC/HDL-C ratio remained un-
changed because of the marked increase in HDL-C.
Women had a greater increase in LDL-C than men.
Older patients had greater increases in TC, LDL-C and
HDL-C. Those with higher BMI had greater increases in
TG, and smaller increases in HDL-C than those with
lower BMI.
In a South African study of 42 patients on an NNRTI-
based first-line regimen the TC, LDL-C, HDL-C and TG
levels (mean ± standard deviation) following 2.1 years of
first-line ART exposure were; 4.75 ± 1.24, 2.65 ± 0.97 and
1.41 ± 0.42 and 1.20 ± 1.18 respectively [13]. In contrast
in our patients after 2.2 years of first-line ART (ie at
switch to second-line ART); TC, LDL-C and HDL-C
levels were lower but TG was higher than in the South
African study. The difference could, at least in part, be
explained by the lower proportion of women in our
study than in the South African study, 48% vs 64% re-
spectively. Indeed there were other important differences
between our two studies. Our patients were predomin-
antly on a triple-nucleoside first-line regimen (86%)
while the South African patients were all on an NNRTI
regimen. However, in a Ugandan study of 374 patients(49% women) who were on a predominantly NNRTI-
based first-line regimen (98% on NVP), lipid levels
(mmol/L) after 2 years were; 3.91; 2.05; 1.22; 1.35; and
3.4 for TC, LDL-C, HDL-C, TG and TC/HDL-C ratio
respectively [14], again TC, LDL-C and HDL-C higher
than values at switch to second-line in our Zimbabwean
study, but lower than in South Africa. Of note, HDL-C
at switch to second-line ART was markedly low in the
Zimbabwean study. Interestingly TG levels were more
similar in all three studies.
The lipid levels in this Zimbabwean African popula-
tion are generally low after exposure to a predominantly
triple nucleoside first-line ART regimen. The choice of
second-line regimens which mostly contained both PI/r
and NNRTIs in our study was dictated by first-line ex-
posure. It is therefore not possible to fully ascribe lipid
changes to either the PI/r or NNRTI class of antiretro-
viral drugs, given the small number of patients not re-
ceiving NNRTI second-line. PI-based regimens have
been associated with elevated lipid levels in several stud-
ies [5,9,27], although the setting of such changes is often
complex [7]. In a study in Benin a significant increase in
TC was observed in a cohort of 88 patients who were on
an NNRTI first-line regimen [28]. Several studies have
shown that NNRTI based regimens are associated with
elevated TC and LDL-C levels [8,9,28] with regimens
combining PIs and NNRTIs showing higher degrees of
dyslipidaemia [8]. Various members of the PI class have
been shown to have varying effects on lipid changes. In
a South African study, after 48 weeks of first-line ART,
there was a smaller rise in LDL-C level with an Atazanavir
based regimen compared to a Nelfinavir based regimen.
Indeed in comparison to Nelfinavir, Atazanvir exposure
was not associated with clinically relevant increases in TC,
LDL-C or TG. Another limitation of our study is that we
did not have a sufficient numbers of patients on EFV ver-
sus those on NVP to allow comparison of the impact
of these two NNRTIs on lipid change. The percentage in-
creases in TC, HDL-C and TG were high, but because of
Gomo et al. AIDS Research and Therapy 2014, 11:32 Page 7 of 8
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the levels attained after exposure to second-line ART were
modest.
In this study an almost equal number of men and
women of similar ages were recruited which gives us the
opportunity to compare lipid changes between men and
women unlike studies in resource-rich countries which
have predominantly studied men. The fact that women
had higher lipid levels than men at switch and 48 weeks
later is difficult to explain since normally men have
higher athrogenic lipids than women [18]. A partial ex-
planation may be the higher BMI in females compared
to males. Indeed both men and women had similar de-
grees of immunosuppression as shown by similar CD4
counts.
Because of the generally low level of lipids in African
populations the facilities to perform lipid assays are lim-
ited and expensive. It may therefore not be possible to
give a recommendation on routine monitoring of lipids,
or even how often lipid levels should be monitored in
this population. This preliminary study suggests that
lipid changes do occur over the short-to-medium term
on second-line LPV/r containing regimens, but are gen-
erally mild abnormalities, and are at least partially offset
(in terms of cardiovascular risk) by increases in HDL-C,
furthermore our results are limited by the short follow-
up period. The best approach for the time being may,
therefore, be to recommend assessment of total athero-
genic risk ie risk factors such as smoking, hypertension,
diabetes, BMI and family history to guide monitoring for
and indeed treatment of lipids in individual patients. We
await further studies to provide more general guidelines
on the monitoring and management of lipids during
ART based on risk factors for cardiovascular disease,
and the impact of various classes of antiretroviral drugs
or individual agents.
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